Sodium bicarbonate
DrugSodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
NCT Number: NCT00706771
The investigators will determine the feasibility, safety and efficacy of intravenous sodium bicarbonate in reducing progression to overt acute renal failure in patients with the systemic inflammatory response syndrome, and low urine output or early acute renal impairment as defined by serum neutrophil gelatinase-associated lipocalin (NGAL).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Austin Hospital, Heidelberg, Melbourne, Victoria, Australia
The investigators hypothesise:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
temperature > 38°C or < 36°C OR heart rate > 90 beats/min OR respiratory rate > 20 breaths/min. PaCO2 < 32 mm Hg OR alteration of white blood cell count > 12,000 cells/mm3, < 4,000 cells/mm3, or the presence of > 10% immature neutrophils
Exclusion criteria
Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
Time frame: 28 days
Time frame: 28 days
Time frame: 28 days
Time frame: 28 days
Austin Health
Other Gov
A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels
Acronym: BLISS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03401190
Acute Pancreatitis, Digestive System Diseases
Detroit, Michigan, United States
View Trial DetailsNCT05979207
Anti-Infective Agents, Antimalarials
Brisbane, Queensland, Australia
View Trial DetailsNCT07231731
Arterial Occlusive Diseases, Arteriosclerosis
Osijek, Croatia
View Trial DetailsNCT04681066
Acute Pancreatitis, Digestive System Diseases
Long Beach, California, United States
View Trial Details